Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).   Recruitment status was  Recruiting

First Received on March 7, 2007.  
Last Updated on August 21, 2010  
History of Changes
Sponsor: Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00445965
  Purpose

RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases.

PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Intraocular Melanoma
Lung Cancer
Melanoma (Skin)
Metastatic Cancer
Neuroblastoma
Ovarian Cancer
Retinoblastoma
Sarcoma
Small Intestine Cancer
Other: immunologic technique
Other: pharmacological study
Radiation: iodine I 131 monoclonal antibody 3F8
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

  • Six-month overall survival [ Designated as safety issue: No ]

Estimated Enrollment: 34
Study Start Date: January 2006
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

  • Determine if intrathecal iodine I 131 monoclonal antibody 3F8 activity in patients with GD2-expressing central nervous system or leptomeningeal neoplasms is sufficiently promising (i.e., 6-month overall survival rate ≥ 25%) to warrant further study.
  • Determine the response rate in patients treated with this drug.
  • Determine the cumulative toxicities of this drug in these patients.
  • Describe the effects of human-antimouse antibody on cerebrospinal fluid and serum pharmacokinetics in patients treated with this drug.
  • To assess the pharmokinetics and dosimetry of intrathecal iodine I 124 monoclonal antibody 3F8/PET imaging.

OUTLINE: This is an open-label study.

Patients receive intrathecal iodine I 124 monoclonal antibody 3F8 for dosimetry. Beginning approximately 1 week later, patients receive intrathecal iodine I 131 monoclonal antibody 3F8 on day 1. Treatment intrathecal iodine I 131 monoclonal antibody 3F8 repeats weekly for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Blood and cerebrospinal fluid samples are collected prior to and after administration of each course of study drug. Samples are analyzed to assess the intrathecal and blood pharmacokinetics of iodine I 131 monoclonal antibody 3F8 and serum human antimouse antibodies.

After completion of study treatment, patients are followed periodically for 3 months.

PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed GD2-expressing malignancy, including the following:

    • Medulloblastoma or primitive neuroectodermal tumor of the CNS
    • High-grade astrocytoma
    • Malignant glioma
    • Neuroblastoma
    • Retinoblastoma
    • Ependymoma
    • Rhabdoid tumors
    • Sarcomas
    • Melanoma
    • Small cell lung carcinoma
    • Desmoplastic small round cell tumor
    • Other tumor types with GD2 expression confirmed by immunohistochemical staining and assessed by the Memorial Sloan-Kettering Department of Pathology using prior frozen tissue, bone marrow, or cerebrospinal fluid cytology
  • Must meet 1 of the following criteria:

    • Refractory to conventional therapies
    • Disease for which no conventional therapy exists
    • Recurrent brain tumors with a predilection for leptomeningeal dissemination (e.g., medulloblastoma, supratentorial primitive neuroectodermal tumor, rhabdoid tumor)
  • Patients with active malignancy outside the central nervous system are eligible

    • No obstructive or symptomatic communicating hydrocephalus

PATIENT CHARACTERISTICS:

  • Absolute neutrophil count > 1,000/mm³
  • Platelet count > 50,000/mm³
  • No uncontrolled life-threatening infection
  • No rapidly progressing or deteriorating neurologic examination
  • No severe major organ toxicity (i.e., renal, cardiac, hepatic, pulmonary, and gastrointestinal system toxicity ≤ grade 2)
  • Stable neurological deficits (due to brain tumor) allowed
  • No hearing loss > 3
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  • No cranial or spinal irradiation within the past 3 weeks
  • No prior craniospinal radiation > 45 Gy or focal brain radiation > 72 Gy
  • No systemic chemotherapy within the past 3 weeks (corticosteroids allowed)
  • Programmable shunt allowed
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00445965

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Kim Kramer, MD     212-639-6410     kramerk@mskcc.org    
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Study Chair: Kim Kramer, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:

No publications provided

Responsible Party: Kim Kramer, Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00445965    
History of Changes
Other Study ID Numbers: CDR0000534394, MSKCC-05122
Study First Received: March 7, 2007
Last Updated: August 21, 2010
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):

recurrent childhood medulloblastoma
untreated childhood medulloblastoma
adult supratentorial primitive neuroectodermal tumor (PNET)
recurrent childhood supratentorial primitive neuroectodermal tumor
untreated childhood supratentorial primitive neuroectodermal tumor
adult anaplastic astrocytoma
adult diffuse astrocytoma
adult pilocytic astrocytoma
adult subependymal giant cell astrocytoma
recurrent childhood subependymal giant cell astrocytoma
untreated childhood subependymal giant cell astrocytoma
recurrent childhood cerebellar astrocytoma
recurrent childhood cerebral astrocytoma
untreated childhood cerebellar astrocytoma
adult brain stem glioma
adult mixed glioma
childhood mixed glioma
recurrent childhood brain stem glioma
recurrent childhood visual pathway and hypothalamic glioma
recurrent childhood visual pathway glioma
untreated childhood brain stem glioma
untreated childhood visual pathway and hypothalamic glioma
untreated childhood visual pathway glioma
regional neuroblastoma
disseminated neuroblastoma
recurrent neuroblastoma
extraocular retinoblastoma
recurrent retinoblastoma
adult anaplastic ependymoma
adult ependymoblastoma

Additional relevant MeSH terms:

Lung Neoplasms
Melanoma
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Nervous System Neoplasms
Neuroblastoma
Ovarian Neoplasms
Retinoblastoma
Central Nervous System Neoplasms
Duodenal Neoplasms
Ileal Neoplasms
Jejunal Neoplasms
Astrocytoma
Neuroectodermal Tumors, Primitive
Uveal Neoplasms
Desmoplastic Small Round Cell Tumor
Intestinal Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Meningeal Neoplasms
Sarcoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

  

  

  

three × two =